hVIVO plc Directors' Dealings (7508S)
05 October 2017 - 5:00PM
UK Regulatory
TIDMHVO
RNS Number : 7508S
hVIVO plc
05 October 2017
For immediate release 7.00am: 5 October 2017
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, announces that
application has been made to AIM for the admission of 23,196 new
ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively
per quarter. On 7 June 2017, Jaime Ellertson volunteered to reduce
his Director's fee by 10% to $180k pa, and his quarterly purchase
of shares by 10% to $18,000, with effect from 1 June '17.
The New Ordinary Shares represent their investments for the
quarter ended 30 September 2017. On 4 October 2017, Mr Ellertson
invested in an additional 17,863 ordinary shares and Mr Winschel
invested in an additional 5,333 ordinary shares, at a price of 75.0
pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,173,867 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 9 October 2017. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 112,413 and 50,123 ordinary shares of 5.0p in the Company
respectively, representing 0.1% and less than 0.1% of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
--- -------------------------------------------------------------------------
a) Name Jaime Ellertson and Jim Winschel
--- ------------------------- ----------------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------------
a) Position/ Non-Executive Chairman and Non-Executive
status Director
--- ------------------------- ----------------------------------------------
b) Initial notification/ Initial Notification
Amendment
--- ------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -------------------------------------------------------------------------
a) Name hVIVO plc
--- ------------------------- ----------------------------------------------
b) Legal Entity N/A
Identifier
--- ------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
--- ------------------------- ----------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
--- ------------------------- ----------------------------------------------
c) Currency GBP
--- ------------------------- ----------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) ----------------- ---------- -------
Jaime Ellertson 75.0 17,863
----------------- ---------- -------
Jim Winschel 75.0 5,333
----------------- ---------- -------
--- -------------------------
e) Aggregated
information
- Aggregated
volume
- Price 23,196
- Aggregated 75.0p
total
GBP17,397.00
--- ------------------------- ----------------------------------------------
f) Date of the 4 October 2017
transaction
--- ------------------------- ----------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--- ------------------------- ----------------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial &
Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell
(UK) +44 203 727 1000
John Capodanno / Evan Smith (US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 50 clinical
studies, inoculated over 2500 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGGRWUUPMPPC
(END) Dow Jones Newswires
October 05, 2017 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024